METHOD FOR DIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROME IN PATIENTS WITH THROMBOSIS AND/OR OBSTETRIC PATHOLOGY Russian patent published in 2023 - IPC G01N33/53 

FIELD: clinical medicine, rheumatology.

SUBSTANCE: used for the diagnosis of antiphospholipid syndrome-APS in patients with thrombosis and/or obstetric pathology. To do this, the patient’s venous blood is taken and the following antiphospholipids - aPL - are determined in the blood samples: IgG/IgM aCL, IgG/IgM anti-β ₂ GP1, VA, IgA aCL, IgA anti-β ₂ GP1, IgG anti-β ₂ GP1DI, IgG/IgM aPs/Pt. First, the determination of IgG/IgM aCL, IgG/IgM anti-β2GP1 is carried out by enzyme immunoassay - ELISA and the study of lupus anticoagulant – VA. When negative values are obtained, IgG/IgM aCL, IgG/IgM- anti-β₂ GP1 using chemiluminescent analysis - CLA and when any of the aPL being studied is identified and is positivity confirmed after 12 weeks, a diagnosis of APS is made. In the absence of IgG/IgM aCL, IgG/IgM anti-β₂ GP1 carry out the determination of IgA aCL, IgA anti-β₂ GP1, IgG anti-β₂ GP1DI by the CLA method and IgG/IgM aPS/Pt by the ELISA method and if any of the studied aPL is detected and is positivity confirmed after at least 12 weeks, a diagnosis of APS is made.

EFFECT: verifying APS in patients with thrombosis and/or obstetric pathology with a high degree of probability.

1 cl, 3 ex, 3 tbl, 1 dwg